ALLMedicine™ Metastatic Breast Cancer Center

May 14th, 2022 - Comprehensive breast cancer management is essential to achieve high breast cancer survival; however, detailed reports of the treatment regimens received by patients are scarce in sub-Saharan Africa where survival is low. We aimed to examine treatm...

May 14th, 2022 - Patients with breast cancer and brain metastases (BM) have a poor prognosis and high clinical need for novel treatments; however, historically, studies have often excluded these patients. Although the BEACON study did not meet its primary end poin...

May 14th, 2022 - Metastatic hormone receptor positive (HR+)/human epidermal growth factor receptor-2 negative (Her2-) breast cancer remains a significant cause of cancer-related mortality. First-line treatment with endocrine therapy (ET) with a cyclin-dependent ki...

May 13th, 2022 - Background: Kaposi Sarcoma (KS) is a multicentric angioproliferative tumor, caused by Kaposi sarcoma-associated herpesvirus, that most frequently involves the skin, but may also involve lymph nodes, lungs, bone and gastrointestinal tract. It is mo...

May 11th, 2022 - After the diagnosis of cancer patients require a lot of information because the disease affects all aspects of life. Some important issues regarding optimal counseling remain to be determined. This includes the time-related relevance of various to...

Oct 23rd, 2021 - ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer.|2021|Gennari A,André F,Barrios CH,Cortés J,de Azambuja E,|diagnosis,therapy,

Apr 8th, 2020 - Several new systemic therapy options have become available for patients with metastatic breast cancer, which have led to improvements in survival. In addition to patient and clinical factors, the treatment selection primarily depends on the tumor ...

Oct 17th, 2017 - Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update Summary.|2017|Van Poznak C,Somerfield MR,Moy B,|therapeutic use,drug therapy,secondary,drug therapy,pa...

May 25th, 2016 - To develop recommendations about endocrine therapy for women with hormone receptor (HR) -positive metastatic breast cancer (MBC). The American Society of Clinical Oncology convened an Expert Panel to conduct a systematic review of evidence from 20...

Sep 4th, 2014 - To identify optimal chemo- and targeted therapy for women with human epidermal growth factor 2 (HER2)- negative (or unknown) advanced breast cancer. A systematic review of randomized evidence (including systematic reviews and meta-analyses) from 1...

May 13th, 2022 - Background: Kaposi Sarcoma (KS) is a multicentric angioproliferative tumor, caused by Kaposi sarcoma-associated herpesvirus, that most frequently involves the skin, but may also involve lymph nodes, lungs, bone and gastrointestinal tract. It is mo...

May 11th, 2022 - PRIMARY OBJECTIVE: I. To identify predictive immune biomarkers and mechanisms of response to ribociclib or palbociclib in advanced, hormone receptor positive breast cancer patients. SECONDARY OBJECTIVES: I. Identify changes in antigen presentation...

May 10th, 2022 - This study is a multicenter, randomized, open-label, two treatment arm, efficacy and safety study. Subjects will be randomized to the two treatment arms in a 1:1 fashion. The primary efficacy endpoint of the study will be the median rPFS. Subjects...

May 10th, 2022 - A Phase I, Open-label, Multicentre, Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AZD2014 Administered Orally in Combination with Intramuscular (IM) Fulvestrant to Patients with Estrogen Receptor Positive (...

May 10th, 2022 - A Global, Single Arm, Phase 2 Study of ARX788 in HER2-positive, Metastatic Breast Cancer Patients whose disease is Resistant or Refractory to T-DM1, and/or T-DXd, and/or Tucatinib-containing Regimens. The ARX788 will be administered every 3 weeks ...

May 6th, 2022 - HER2 expression appeared to be a significant predictor for response to fam-trastuzumab deruxtecan-nxki (Enhertu), according to findings from a biomarker analysis of patients with metastatic breast cancer in the phase 2 DAISY trial (NCT04132960) pr...

May 6th, 2022 - The combination of alpelisib (Piqray) plus endocrine therapy elicited a clinical benefit across all subgroups of patients with hormone receptor (HR)–positive, HER2-negative advanced breast cancer with PIK3CA mutations, according to data from a sub...

May 5th, 2022 - The US Food and Drug Administration (FDA) has granted standard approval to fam-trastuzumab deruxtecan-nxki (Enhertu) for patients with unresectable or metastatic HER2-positive breast cancer who have received one prior anti-HER2 therapy. This stand...

Apr 29th, 2022 - Erin Roesch, MD The phase 2 DESTINY-Breast01 trial showed impressive antitumor activity with the antibody-drug conjugate trastuzumab deruxtecan (T-DXd) in a heavily pretreated patient population with metastatic human epidermal growth factor recept.

Apr 29th, 2022 - Significant progress has shifted the treatment paradigm in various spaces within breast cancer, including therapy options for patients with HER2-positive metastatic breast cancer, hormone receptor (HR)–positive, HER2-negative breast cancer, and tr...